Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Pipeline Review, H2 2017
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Pipeline Review, H2 2017
SUMMARY
According to the recently published report 'Metabotropic Glutamate Receptor 1 - Pipeline Review, H2 2017'; Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) pipeline Target constitutes close to 7 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Metabotropic glutamate receptor 1 (mGluR1) is a protein encoded by GRM1. It activates a phosphatidylinositol-calcium second messenger system. It participates in the central action of glutamate in the CNS, such as long-term potentiation in the hippocampus and long-term depression in the cerebellum.
The report 'Metabotropic Glutamate Receptor 1 - Pipeline Review, H2 2017' outlays comprehensive information on the Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology and Genetic Disorders which include indications Melanoma, Attention Deficit Hyperactivity Disorder (ADHD), Depression, DiGeorge Syndrome, Generalized Anxiety Disorder (GAD), Infantile Spasm (West Syndrome), Pervasive Developmental Disorder (PDD), Schizophrenia and Status Epilepticus.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Metabotropic Glutamate Receptor 1 - Pipeline Review, H2 2017'; Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) pipeline Target constitutes close to 7 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Metabotropic glutamate receptor 1 (mGluR1) is a protein encoded by GRM1. It activates a phosphatidylinositol-calcium second messenger system. It participates in the central action of glutamate in the CNS, such as long-term potentiation in the hippocampus and long-term depression in the cerebellum.
The report 'Metabotropic Glutamate Receptor 1 - Pipeline Review, H2 2017' outlays comprehensive information on the Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology and Genetic Disorders which include indications Melanoma, Attention Deficit Hyperactivity Disorder (ADHD), Depression, DiGeorge Syndrome, Generalized Anxiety Disorder (GAD), Infantile Spasm (West Syndrome), Pervasive Developmental Disorder (PDD), Schizophrenia and Status Epilepticus.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1)
- The report reviews Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Overview
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Companies Involved in Therapeutics Development
Aevi Genomic Medicine Inc
Biohaven Pharmaceutical Holding Company Ltd
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Drug Profiles
fasoracetam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FC-311 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JBPOS-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize mGlu1 for Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize GRM1 for Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize mGluR1 for Depression - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0467558 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Dormant Products
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Product Development Milestones
Featured News & Press Releases
May 10, 2017: Aevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-001
Apr 20, 2017: Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
Apr 12, 2017: Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
Mar 20, 2017: Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001
Jan 31, 2017: Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome
Jan 04, 2017: Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents
Oct 29, 2016: Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder
Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Overview
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Companies Involved in Therapeutics Development
Aevi Genomic Medicine Inc
Biohaven Pharmaceutical Holding Company Ltd
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Drug Profiles
fasoracetam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FC-311 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JBPOS-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize mGlu1 for Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize GRM1 for Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize mGluR1 for Depression - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0467558 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Dormant Products
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Product Development Milestones
Featured News & Press Releases
May 10, 2017: Aevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-001
Apr 20, 2017: Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
Apr 12, 2017: Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
Mar 20, 2017: Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001
Jan 31, 2017: Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome
Jan 04, 2017: Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents
Oct 29, 2016: Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder
Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Aevi Genomic Medicine Inc, H2 2017
Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2017
Dormant Projects, H2 2017
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Aevi Genomic Medicine Inc, H2 2017
Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2017
Dormant Projects, H2 2017
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
COMPANIES MENTIONED
Aevi Genomic Medicine Inc
Biohaven Pharmaceutical Holding Company Ltd
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
COMPANIES MENTIONED
Aevi Genomic Medicine Inc
Biohaven Pharmaceutical Holding Company Ltd
